STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment

A group of outside experts convened by the Food and Drug Administration on Thursday voted in favor of Replimune’s experimental treatment for advanced melanoma. In a 10-3 vote, the advisers determined that the biotech company has collected sufficient data to allow the FDA to review RP1, an engineered viral immunotherapy for melanoma. The agency tends to follow the recommendations of its expert panels but is not bound by them. What comes next could be seen by some as a signal of how the FDA, under...